# CPE CBRND Clarifies Acquisition Role

The Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), formerly JPEO-CBRND, is identified as the Army organization responsible for acquisition in its mission area, distinct from technical research contributions and FDA product authorization. The overview describes past industry engagement involving biomedical research-model supply and technology-partner outreach through the Joint Enterprise Technology Tool (JETT), but identifies no active solicitation, contract award, funding amount, or procurement contact. For contractors, this is organizational and market context—not a current bid opportunity.

- Companies serving the CBRN defense market should distinguish CPE CBRND’s acquisition role from research activities and FDA authorization when assessing where their offerings fit.
- Biomedical research-model suppliers and technology firms can use the article’s account of prior engagement and JETT outreach as background, but it does not announce an open procurement or confirm a current outreach opportunity.
- No contract value, solicitation number, deadline, or procurement contact is provided; the signal does not support a specific bid or proposal action.

**Jurisdictions:** federal
**Industries:** Defense & Military, Healthcare
**Published:** November 17, 2026

### Government Entities
- Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (formerly Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense) (CPE CBRND / JPEO-CBRND)
- U.S. Army (Army)
- Defense Threat Reduction Agency (DTRA)
- U.S. Food and Drug Administration (FDA)

### Sources
- [JPEO-CBRND: Mission and Current CPE Role — CASRAI](https://casrai.org/guides/jpeo-cbrnd) - CASRAI